Results 81 to 90 of about 2,398,753 (259)

ADP‐ribosylation: An emerging regulator of the epigenome

Molecular Oncology, EarlyView.
ADP‐ribosylation has emerged as a dynamic epigenetic signaling mechanism that modifies histones and chromatin‐associated proteins. Through coordinated PARylation and MARylation, it integrates with other histone modifications to regulate chromatin structure, transcription factor activity, and gene expression, influencing genome function and disease ...
Cristel V. Camacho, Chenqian Liu, W. Lee Kraus   +2 more
wiley   +1 more source

Targeted drug conjugates in cancer therapy: Challenges and opportunities

Pharmaceutical Science Advances
Traditional chemotherapy is often accompanied by off-target toxicity, resulting in adverse side effects and driving the development of targeted therapies.
Geng Jia, Yuqi Jiang, Xiaoyang Li
doaj   +1 more source

Antibody responses to nasopharyngeal carriage of Streptococcus pneumoniae in adults: A longitudinal household study [PDF]

, 2005
Background. Natural immunity to Streptococcus pneumoniae is thought to be induced by exposure to S. pneumoniae or cross-reactive antigens. No longitudinal studies of carriage of and immune responses to S.
Hussain, M, Virta, C, Soininen, A, Kayhty, H, Miller, E, Ashton, L, Edmunds, J, Gay, N, Goldblatt, D, Andrews, N, George, R, Pebody, R, Melegaro, A   +12 more
core  

Multiplex Bioanalytical Methods for Comprehensive Characterization and Quantification of the Unique Complementarity-Determining-Region Deamidation of MEDI7247, an Anti-ASCT2 Pyrrolobenzodiazepine Antibody–Drug Conjugate

, 2023
Deamidation, a common post-translational modification, may impact multiple physiochemical properties of a therapeutic protein. MEDI7247, a pyrrolobenzodiazepine (PBD) antibody–drug conjugate (ADC), contains a unique deamidation site, N102, located ...
Kathryn Ball, Dengfeng Liu, Robert J. Kubiak, Yue Huang, Jiaqi Yuan, Niluka de Mel, Lorin K. Roskos, Anton I. Rosenbaum, Meina Liang, Ruipeng Mu, Mingyan Cao, G. Patrick Hussmann   +11 more
core   +1 more source

Castration‐resistant prostate cancer cells are addicted to the high activity of cyclin‐dependent kinase 2

Molecular Oncology, EarlyView.
We show that emergence of castration‐resistant prostate (CRPC) is associated with significant upregulation of cyclins that positively regulate cyclin‐dependent kinase 2 (CDK2) and concomitant downregulation of CDK4 cyclins. This renders CRPC cells dependent on the high activity of CDK2, and CDK2 inhibitors synergistically sensitize CRPC cells to both ...
Joyeeta Chatterjee, Alessia Marin, Shivani Yalala, Harri M. Itkonen   +3 more
wiley   +1 more source

Intracellular trafficking of new anticancer therapeutics: antibody–drug conjugates

, 2017
Muhammad Kalim,1 Jie Chen,1 Shenghao Wang,1 Caiyao Lin,1 Saif Ullah,1 Keying Liang,1 Qian Ding,1 Shuqing Chen,2 Jinbiao Zhan1 1Department of Biochemistry and Genetics, School of Medicine, 2Department of Pharmaceutical Analysis, College of Pharmaceutical
Ullah S, Lin C, Chen J, Wang S, Liang K, Kalim M, Ding Q, Chen S, Zhan JB   +8 more
core  

Supplementary Table S4 from Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index

, 2008
Supplementary Table S4 from Engineered anti-CD70 antibody-drug conjugate with increased therapeutic ...
Eileen Turcott (15041066), Ivan Stone (15036102), Hans-Peter Gerber (4261570), Lori Westendorf (15036087), Charlotte F. McDonagh (14973178), Stephen C. Alley (1897735), Django Sussman (1934839), Martha Anderson (1934836), Paul J. Carter (3387371), Tiffany Feist (15036093), Jamie Miyamoto (15041069), Kristine M. Kim (15036084), Lindsay L. Brown (15036090), Robert Lyon (15036096)   +13 more
core   +1 more source

Mechanisms and therapeutic opportunities of the ribotoxic stress response in cancer

Molecular Oncology, EarlyView.
Cancer cells' high translational demand creates opportunities to therapeutically target ribosome function. Ribosome stalling and collisions activate ZAKα and the ribotoxic stress response (RSR), which can trigger rapid, p53‐independent apoptosis in cancer.
Anastassiya Kim, Maryam Aslam, Elouise Torruella, Alphons Sony, Asif Rahman, Simira Smith, Columba de la Parra, Moira Sauane   +7 more
wiley   +1 more source

Antibody-Drug Conjugate Sequencing in Metastatic Breast Cancer

healthbook TIMES. Oncology Hematology
Antibody-drug conjugates (ADCs) have redefined the therapeutic paradigm of metastatic breast cancer by combining targeted antibody specificity with potent cytotoxic payloads. The regulatory approvals of sacituzumab govitecan (SG), trastuzumab deruxtecan (
Benjamin Müller, Marcus Vetter
doaj   +1 more source

Supplementary Fig. S2 from Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index

, 2008
Supplementary Fig.
Eileen Turcott (15041066), Ivan Stone (15036102), Hans-Peter Gerber (4261570), Lori Westendorf (15036087), Charlotte F. McDonagh (14973178), Stephen C. Alley (1897735), Django Sussman (1934839), Martha Anderson (1934836), Paul J. Carter (3387371), Tiffany Feist (15036093), Jamie Miyamoto (15041069), Kristine M. Kim (15036084), Lindsay L. Brown (15036090), Robert Lyon (15036096)   +13 more
core   +1 more source